ClinicalTrials.gg
RecruitingNCT07357675EasyBoostUpdated Nov 2, 2026

A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.

A Phase 3 interventional study of EA-230 90mg/kg/hour and Placebo in Coronary Artery Disease (CAD) and Coronary Artery Bypass Graft Surgery(CABG), sponsored by EBI Anti Sepsis BV. Recruiting at 6 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by EBI Anti Sepsis BV · Phase 3, Interventional, and Treatment

How we know

Updated Nov 2, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,104 studies in Coronary Artery Disease with a site in United States — 99 open to participants now, 144 under way, 10 of them phase 3. Coronary Artery Disease · United States.

Planned enrollment
212th of 745
300 · median 107
Started
2026
with 23 others
Phase 3
101 of 1,104
4 open now
Primary completion
2027-10
later than 84 of 141 live
Registered
1,086th of 1,104
by date

Among the 1,104 studies in Coronary Artery Disease with a site in United States, this one is the 212th largest by planned enrollment of the 745 interventional ones that give a count, is one of 24 that started in 2026, is one of 101 in phase 3, reaches primary completion later than 84 of the 141 other live ones, and was the 1,086th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

99 of the 1,104 studies in Coronary Artery Disease with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 99 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,104 studies in Coronary Artery Disease with a site in United States, or all of them as a file.
02

Study summary

EA-230 is a new therapy that may help people recover faster and have fewer problems after bypass surgery. In an earlier clinical trial, participants who received EA-230 during Coronary Artery Bypass surgery stayed in the Intensive Care Unit (ICU) and the hospital for a shorter time and had fewer serious complications, compared to those who received a placebo (an inactive therapy). The use of EA-230 was safe and well tolerated. This trial will test EA-230 in more participants to see if it really works and is safe to use in the future.

This is a Phase III trial. It will take place in multiple locations and will follow a double-blind, randomized, placebo-controlled clinical design, meaning neither doctors nor participants will know whether they receive EA-230 or placebo during the trial. Assignment to EA-230 or placebo occurs by chance, like throwing dice. The total duration of the trial, including medical check-ups, will be approximately 71 days. There is a total of 10 visits, including a screening-, a pre-operative-, and 2 remote visits. 7 of these visits are during your stay at the hospital.

Read the detailed description

The sites and vendor have been selected, and no further engagement regarding acquisition will be considered.

03

Conditions studied

  • Coronary Artery Disease (CAD)
  • Coronary Artery Bypass Graft Surgery(CABG)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged ≥18 years, both male and female.
  2. Patients scheduled for elective on-pump CABG with at least 3 bypasses, with or without valve replacement.
  3. Willing and able to give written .

Exclusion criteria

Exclusion Criteria:

  1. Patients undergoing non-elective on-pump CABG (i.e., emergency surgery). Emergency surgery is defined as planned surgery within 24 hours of diagnosis.
  2. Cardiogenic shock or hemodynamic instability that requires inotropes, vasopressors, or other mechanical devices, such as an intra-aortic balloon counter-pulsation (IABP), within 24 hours prior to surgery.
  3. Use of a left ventricular assist device (LVAD), or intra-aortic balloon pump or other cardiac devices, within 7 days prior to surgery.
  4. A requirement for any of the following within 7 days prior to surgery: defibrillator or permanent pacemaker, mechanical ventilation, IABP, LVAD, or other forms of mechanical circulatory support.
  5. Required cardiopulmonary resuscitation within 14 days prior to cardiac surgery.
  6. Known chronic liver disorder with C classification.
  7. Confirmed or treated endocarditis requiring antimicrobial or antiviral treatment within 30 days prior to surgery or other current active infection requiring antimicrobial or antiviral treatment within 14 days prior to surgery.
  8. Ongoing sepsis (as defined by SEPSIS-3) within 2 weeks of screening or, in the opinion of the investigator, an untreated infection (viral or bacterial) prior to or at Screening and before randomization.
  9. Immuno-compromised patients, as self-reported or as observed in medical records, including patients:

    1. with solid organ transplantation.
    2. known to be positive for (HIV).
    3. that use drugs or have received recent chemotherapy, at the discretion of the Investigator and including patients;

    i. with active who have undergone chemotherapy within 30 days prior to trial entry.

    ii. receiving chronic treatment equivalent to a prednisone dose of 10 mg or higher per day, within 30 days prior to trial entry, or an equivalent dose of another corticosteroid or any other anti-inflammatory or inflammation-suppressing medications such as interleukin blockers, methotrexate or similar therapies. Non-Steroidal Anti-Inflammatory Drugs are not exclusionary.

  10. Patients with hematological disorders (known disorders from myeloid and/or lymphoid origin, leucopenia (both active and in remission)).
  11. Known severe renal disease requiring dialysis, or a known estimated (eGFR) prior to admission of \< 20 ml/min/1.73 m2.
  12. Previous receipt of EA-230.
  13. Known to the IMP.
  14. Use of any drug within 1 month or 5 half-lives of said investigational drug (whichever is longer) prior to IMP administration in this trial. Participation in an observational clinical trial is not exclusionary.
  15. Women who are pregnant, breastfeeding or planning to become pregnant during the trial or within 28 days after IMP administration ( must have a negative pregnancy test prior to entry into the trial).
  16. Female patients of childbearing potential who are not willing/able to use adequate and refrain from donating ova from enrolment and up to 28 days after IMP administration (contraceptive requirements are detailed in Annex 5. Contraceptive Guidance).
  17. Male patients who are not willing/able to use adequate contraception (if their partners is of childbearing potential) and refrain from donating sperm from enrolment and up to 28 days after IMP administration (contraceptive requirements are detailed in Annex 5. Contraceptive Guidance).
  18. Inability to personally provide written .
  19. Known or suspected of not being able to comply with the trial protocol, at the discretion of the Investigator.
  20. Any other condition which, in the Investigator's opinion, will interfere with completion of the trial.
  21. Being an employee of the Investigator or trial site with direct involvement in the proposed trial or other studies under the direction of that Investigator or trial site or being a family member of an employee of the Investigator with direct involvement in the proposed trial.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    EA-230 90mg/kg/hour

    Drug: EA-230 90mg/kg/hour

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Required postoperative hospital length of stay

    Median postoperative duration, from the moment of first incision until the time when a patient is eligible to be discharged from the hospital.

    Time frame: Up to 28 days

Secondary outcomes

  1. the effect of EA-230 on the duration of moderate and severe POCs

    Median cumulative duration of moderate and severe Single Organ Outcome Measures (SOOMs) according to the European Perioperative Clinical Outcome (EPCO) definitions during the trial.

    Time frame: Up to 28 days

  2. Hemodynamic stability via Net fluid balance

    Median cumulative Net fluid balance (NFB) at the start of IMP administration (T0) and up to 24 and 48 hours thereafter.

    Time frame: Up to 2 days (48 hours) after start of surgery (first incision)

  3. Hemodynamic stability via VIS score

    Cumulative dose of vasopressors and inotropes used and vasopressor-inotropic scores at the start of IMP administration (T0) and up to 24 and 48 hours thereafter, compared between treatment arms. Up to 2 days (48 hours) after start of surgery (first incision)

    Time frame: Up to 2 days (48 hours) after start of surgery (first incision)

  4. Required postoperative ICU length of stay

    Median postoperative duration, from the moment of first incision until the time when a patient is eligible to be discharged from the ICU and transferred to the general ward.

    Time frame: Up to 28 days

  5. Actual postoperative ICU and hospital length of stay

    Median postoperative duration, from the moment of first incision until the time when a patient is actually discharged from the ICU, and discharged from the hospital

    Time frame: Up to 28 days

  6. Blood plasma levels of EA-230 in microgram per liter (µg/L)

    Blood plasma levels of EA-230 measured immediately before the end of EA-230 infusion (T4) in all patients. Blood plasma levels of EA-230 measured at T0, T0.5, T1, T2, T3 and T4 in a subset of patients in the Netherlands. Only venous blood is sampled to determine blood plasma levels.

    Time frame: Up to 4 hours after IMP administration (on Day 1)

  7. Safety assessment of EA-230

    Incidence of treatment emergent (Serious) Adverse Events and Adverse Drug Reactions during the trial period. Coded using the Medical Dictionary for Regulatory Activities (version 28 or higher) and graded according to the Common Terminology Criteria for Adverse Events (V6.0).

    Time frame: Up to 28 days

07

Study locations

3 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The IPD might be shared in the future, this is currently undecided. This field will be updated in case the data will be shared in the future.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Oct 2027, 11 months after the start.

Of 30 industry-sponsored phase 3 interventional studies under Coronary Artery Disease, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 11 months is below that.

Counting every sponsor, half of 62 studies reached it within 47 months; a quarter within 20 and three quarters within 58.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Aug 2026 → Oct 2026, primary completion Jun 2027 → Oct 2027 and completion Jul 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2026
First posted
Jan 22, 2026
StartActual
Oct 29, 2026was Aug 2026
Primary completionEst.
Oct 1, 2027was Jun 2027
CompletionEst.
Dec 1, 2027was Jul 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 2, 2026
Sites
6 sites changed recruiting status (3 now not yet recruiting, 3 now recruiting)
Show 6 sites
  • MAYO clinic · Rochester, United Statesno status→Not yet recruiting
  • UPMC · Pittsburgh, United Statesno status→Not yet recruiting
  • UZ Gent · Ghent, Belgiumno status→Recruiting
  • Medisch Spectrum Twente · Enschede, Netherlandsno status→Recruiting
  • RadboudUMC · Nijmegen, Netherlandsno status→Recruiting
  • St Thomas' Hospital · London, United Kingdomno status→Not yet recruiting
Nov 2, 2026
Start date
Aug 1, 2026→Oct 29, 2026 (actual)
Nov 2, 2026
Primary completion
Jun 1, 2027→Oct 1, 2027
Nov 2, 2026
Study completion
Jul 1, 2027→Dec 1, 2027
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Not yet recruiting→Recruiting
    6 sites changed recruiting status (3 now not yet recruiting, 3 now recruiting)
    Show 6 sites
    • MAYO clinic · Rochester, United Statesno status→Not yet recruiting
    • UPMC · Pittsburgh, United Statesno status→Not yet recruiting
    • UZ Gent · Ghent, Belgiumno status→Recruiting
    • Medisch Spectrum Twente · Enschede, Netherlandsno status→Recruiting
    • RadboudUMC · Nijmegen, Netherlandsno status→Recruiting
    • St Thomas' Hospital · London, United Kingdomno status→Not yet recruiting
    Start date Aug 1, 2026→Oct 29, 2026 (now actual)
    Primary completion Jun 1, 2027→Oct 1, 2027
    Study completion Jul 1, 2027→Dec 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07357675
Lead sponsor
EBI Anti Sepsis BV
Collaborators
CR2O B.V.
Responsible party
Sponsor
First posted
Jan 22, 2026
Start date
Oct 29, 2026
Primary completion
Oct 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Bas Ossenkoppele, Msc
Contact
bas.ossenkoppele@cr2o.nl
+31 620033017
Leonie Koomen, Msc
Contact
leonie.koomen@cr2o.nl
+31610518323
Peter Pickers, Prof.
principal investigator · Radboudmc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alanyl-glutaminyl-glycyl-valine

Start the discussion